COOPER COMPANIES (COO) Company Report

Cooper Companies, Inc. entered into Amendment No. 3 to its Amended Term Loan Agreement (originally dated December 17, 2021), effective February 3, 2026, with multiple subsidiary guarantors and lenders consenting to the amendment.
Its amended credit facilities comprise a $2.3 billion revolving facility and a $1.5 billion term loan facility, with PNC Capital Markets LLC and Citi among the joint bookrunners and lead arrangers.

3 days ago

8-K

Cooper Companies outlines strategy and guidance at J.P. Morgan Healthcare Conference

COO

Guidance Update

Share Buyback

Product Launch

Two business units: CooperVision (number one globally by wearers, number two by revenue) and CooperSurgical (fertility and women’s healthcare) generated $4.1 billion in revenues with a 10-year CAGR of 8.6% (Vision 6.3%, Surgical 16%); over 50% of sales in the Americas, followed by Europe and Asia-Pac.
Fiscal 2026 guidance calls for Q1 non-GAAP EPS of $1.02–$1.04, full-year EPS of $4.45–$4.60, and free cash flow of $575–$625 million, reflecting the tail-off of heavy CapEx and improved cash conversion.
Organic growth and efficiency focus: Post-reorg and ERP upgrades, targeting $50 million in annual cost synergies, disciplined capital allocation with ~2/3 of FCF on share buybacks (≈$1 billion authorization remaining), and AI-driven headcount and inventory optimizations.
Leading the $11 billion contact lens market (4–6% annual growth) driven by myopia prevalence, ~1% pricing, ~1% wearer growth, and shift to daily SiHy and multifocals; CooperVision’s share rose from 22% to 27% over 10 years, with recent launches including MyDay MiSight in Europe and MyDay Energys in Q2.
CooperSurgical’s fertility segment (39% of surgical revenues; $3 billion market, mid-single-digit growth) benefits from delayed childbirth (U.S. average maternal age 30), reimbursement trends, and a refreshed product pipeline after a recent clinic-driven growth pullback.

Jan 14, 2026, 10:15 PM

Transcript

CooperCompanies provides FY26 financial guidance at 44th Annual J.P. Morgan Healthcare Conference

COO

Guidance Update

Provided Q1 2026 revenue guidance of $1,019 – $1,030 M (3 – 4% organic growth) and FY 2026 guidance of $4,299 – $4,338 M (4.5 – 5.5% organic growth), with non-GAAP EPS of $4.45 – $4.60
Total revenue more than doubled over the last decade, with CooperVision at $2,744 M and CooperSurgical at $1,349 M in FY 2025
Targets double-digit EPS growth and fiscal 2026–2028 free cash flow exceeding $2.2 B, allocating ~ 2/3 of FY 2026 FCF to share buybacks
#1 contact lens company with 33% global wearer share and a leading fertility business in a ~$3 B market growing 4 – 6%, alongside an extensive office & surgical device platform

Jan 14, 2026, 10:15 PM

Presentation

Cooper Companies presents FY2026 guidance and strategic priorities

COO

Guidance Update

Product Launch

M&A

Cooper operates two segments: CooperVision, the world’s #1 in contact lens wearers (42 M) and #2 by revenue, and CooperSurgical, a fertility and women’s healthcare business; FY 2025 revenues totaled $4.1 B, with ~2/3 from vision.
FY 2026 guidance includes Q1 non-GAAP EPS $1.02-$1.04, full-year $4.45-$4.60, and free cash flow $575 M–$625 M; free cash flow expected to benefit from reduced CapEx and working-capital improvements.
CooperVision targets mid-single-digit organic growth, supported by private-label wins and a pipeline of new daily silicone hydrogel products (e.g., MyDay MiSight, MyDay Energys) launching in EMEA, APAC, and Japan.
CooperSurgical expects fertility growth to rebound to mid-single-digits in 2026, underpinned by a $3 B global IVF market and long-term demographic trends (1 in 6 couples experiencing infertility).
Launched a strategic review to evaluate standalone versus combined structures, weighing synergies, scale benefits, and tax optimization; outcomes to be shared on the next earnings call.

Jan 14, 2026, 10:15 PM

Transcript

Cooper Companies outlines FY26 guidance and strategic review at JPMorgan Healthcare Conference

COO

Guidance Update

M&A

Share Buyback

Cooper’s FY26 non-GAAP EPS guidance is $1.02–$1.04 for Q1 and $4.45–$4.60 for the full year, with $575M–$625M of free cash flow expected, driven by reduced CapEx and working capital improvements.
The company initiated a strategic review, led by Citigroup, to assess potential separation or transaction of CooperVision and CooperSurgical, balancing $50M of synergy opportunities, scale advantages, and tax benefits against standalone valuation premiums.
CooperVision holds 33% share of global contact lens wearers (#1 by wearers, #2 by revenue), targets mid-single digit market growth with launches such as MyDay MiSight and Energys, and is leveraging private label contract wins to boost penetration.
CooperSurgical’s fertility segment (≈39% of the business) expects improvement from mid-single digit market growth in a $3 billion industry underpinned by delayed childbirth trends, insurance coverage expansions, and new R&D product launches.
The board raised the share repurchase authorization from $1 billion to $2 billion, with plans to deploy one-third to two-thirds of free cash flow annually for buybacks.

Jan 14, 2026, 10:15 PM

Transcript

CooperCompanies reports Q4 2025 results

COO

Earnings

Guidance Update

Share Buyback

Q4 revenue rose 4.6% year-over-year to $1.065 billion, non-GAAP EPS grew 11% to $1.15, and free cash flow was $150 million in the quarter.
Fiscal 2026 guidance targets $4.30–4.34 billion in consolidated revenues (4.5%–5.5% organic growth) and $4.45–4.60 non-GAAP EPS.
Completed a Q4 reorganization incurring $89 million of charges and expected to deliver $50 million of annual pre-tax savings beginning fiscal 2026.
Returned capital via $197 million of share repurchases in Q4 (≈$300 million YTD) and board authorization to increase the repurchase plan to $2 billion; raised 2026–2028 free cash flow target to >$2.2 billion.
Launched a formal strategic review, appointed Colleen Jay as board chair, and added total shareholder return to executive compensation plans.

Dec 4, 2025, 10:00 PM

Transcript

Cooper Companies reports Q4 2025 results and issues FY 2026 guidance

COO

Earnings

Guidance Update

Board Change

Consolidated revenues of $1.065 billion (+4.6% y/y; +3.4% organic), non-GAAP EPS $1.15 (+11%), 27% operating margin and $150 million free cash flow.
CooperVision Q4 revenue of $710 million (+4.9%; +3.2% organic), led by MyDay lens momentum and MiSight growth of 37%, while Asia-Pac was flat (China -28%).
CooperSurgical Q4 revenue of $356 million (+4.0%; +3.9% organic), with fertility at $141 million (+1%) and Office & Surgical at $215 million (+6%).
Fiscal 2026 guidance: Q1 revenues of $1.019–$1.03 billion (3%–4% organic) and EPS $1.02–$1.04; full-year revenues of $4.3–$4.34 billion (4.5%–5.5% organic) and EPS $4.45–$4.60.
Announced a formal strategic review, board chair transition to Colleen Jay, added total shareholder return to executive compensation, and repurchased $197 million of stock in Q4 under a $2 billion program.

Dec 4, 2025, 10:00 PM

Transcript

Cooper Companies issues FY26 and Q1 FY26 financial guidance

COO

Guidance Update

Earnings

FY26 total revenue is guided to $4,299 M–$4,338 M (4.5%–5.5% organic growth).
CooperVision revenue for FY26 is expected at $2,900 M–$2,925 M (4.5%–5.5% organic growth); CooperSurgical at $1,399 M–$1,413 M (4%–5% organic growth).
Q1 FY26 revenue guidance of $1,019 M–$1,030 M (3%–4% organic growth); CooperVision $693 M–$700 M (3.5%–4.5%) and CooperSurgical $327 M–$330 M (2%–3%).
Non-GAAP EPS is projected at $4.45–$4.60 for FY26 and $1.02–$1.04 for Q1 FY26.
FY26 free cash flow is forecast at $575 M–$625 M.

Dec 4, 2025, 10:00 PM

Presentation

CooperCompanies announces Q4 2025 results

COO

Earnings

Share Buyback

Guidance Update

Revenue: Q4 2025 net sales of $1,065.2 M (up 5%, 3% organic); FY 2025 revenue of $4.1 B (up 5%, 4% organic).
Earnings: Q4 GAAP EPS of $0.43 (down 27%), non-GAAP EPS of $1.15 (up 11%); FY GAAP EPS $1.87 (down 4%), non-GAAP EPS $4.13 (up 12%).
Cash flow & guidance: Q4 free cash flow $149.8 M; FY free cash flow $433.7 M; updated free cash flow guidance of >$2.2 B from fiscal 2026–2028.
Share repurchases: Repurchased $197.3 M in Q4 (~2.9 M shares) and $290.1 M in FY 2025 (~4.1 M shares).

Dec 4, 2025, 9:48 PM

8-K

Cooper Companies outlines CVI headwinds, MyDay recovery, and capital return plan

COO

Guidance Update

Share Buyback

Q3 CooperVision organic growth was 2% vs. ~5% expected, driven by accelerated private-label Clarity drawdown in Asia Pac and normalization of six-month to two-month e-commerce channel inventory in China; Q4 guidance is conservatively built to offset these factors.
MyDay supply constraints have been fully resolved as of May, enabling double-digit MyDay growth and supporting ~25% global market share in daily silicone hydrogel lenses.
Management expects the global contact lens market to grow 4–6% in FY26, CooperVision core in line with market plus 100 bps from MiSight, with daily wear penetration at ~40% globally and runway to 50%+.
Targeting $2 billion of free cash flow over three years, with declining CapEx; primary uses include debt paydown and increased share repurchases, supported by a CooperSurgical reorganization to improve margins and offset ~$24 million in tariffs.

Sep 3, 2025, 8:18 PM

Earnings Transcripts

Quarterly earnings call transcripts for COOPER COMPANIES.

Q4 2025

Dec 4, 2025

→

Q3 2025

Aug 27, 2025

→

Q2 2025

May 29, 2025

→

View All Transcripts

Ask Fintool AI Agent

Get instant answers from SEC filings, earnings calls & more

What did Albert White III say about margins?What are COOPER COMPANIES's strategic priorities?How is COOPER COMPANIES positioned vs competitors?How did COOPER COMPANIES do last quarter?

COOPER COMPANIES (COO)

Analyst Earnings Quarterly Reports

Q3 2025

Q2 2025

Q1 2025

Q4 2024

Executives

Albert White III

Agostino Ricupati

Brian Andrews

Daniel McBride

Gerard Warner III

Holly Sheffield

Nicholas Khadder

Board Members

Barbara Carbone

Colleen Jay

Cynthia Lucchese

Lawrence Kurzius

Maria Rivas

Robert Weiss

Teresa Madden

Analyst Coverage

Brett Fishbin

Jason Bednar

David Saxon

Jeffrey Johnson

Jonathan Block

Navann Ty

Anthony Petrone

Craig Bijou

Issie Kirby

Joanne Wuensch

Larry Biegelsen

Robert Marcus

Steven Lichtman

Young Li

Christopher Pasquale

Patrick Wood

Chris Pasquale

Lawrence Biegelsen

Anthony

Bradley Bowers

David Roman

Jeff Johnson

Jon Block

Lily Mowry

Matt Miksic

Navann Ty Dietschi

Robbie Marcus

Travis Steed

Latest news

Earnings Transcripts

Q4 2025

Q3 2025

Q2 2025

Ask Fintool AI Agent